ArticleMolecular nutrition & food research2026
Microalgal Unsaponifiable Matter Ameliorates Estrogen Deficiency-Induced Metabolic Dysfunction Through Intestinal Barrier Restoration and Gut Microbiota Modulation.
Article in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Estrogen deficiency contributes to intestinal barrier dysfunction, inflammation, and metabolic disturbances during the postmenopausal period. This study investigated the protective potential of microalgal unsaponifiable matter (MU) derived from Chlorella sp. against epithelial disruption and metabolic impairments associated with estrogen deficiency. MU was evaluated in tumor necrosis factor-α-challenged Caco-2 cells and ovariectomized mice. In vitro, MU (5-20 µg/mL) preserved cell viability, restored transepithelial electrical resistance (TEER), and maintained tight junction proteins while suppressing nuclear factor kappa-light-chain-enhancer of activated B cells-related cytokine expression. In vivo, MU improved feed efficiency, high-density lipoprotein cholesterol, and hepatic enzyme markers and reduced systemic and adipose tissue inflammation. MU also enhanced intestinal barrier integrity, increased mucin 2 expression, and partially normalized gut microbiota composition, including improvements in the Firmicutes/Bacteroidetes ratio. These compositional changes were associated with improvements in metabolic and inflammatory parameters, though causal relationships between specific microbial taxa and functional outcomes remain to be established. Collectively, these findings suggest that MU supports intestinal barrier protection, attenuates inflammation, and is associated with improved metabolic outcomes under estrogen-deficient conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.